Neurochemical Mechanisms of Addiction

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

The spread of various types of addictions is an actual problem in society. In modern world, filled with various stressors, adults and especially teenagers often fall victim to substance use or other addictions. As a result, addictive patients develop symptoms such as: unmotivated aggression and psychosis associated with craving for drug use; in later stages – anhedonia, depression, suicide attempts, as well as a number of serious illnesses. Thus, the development of drug addiction can lead to irreversible consequences for the psychological and physical health of both addicted people and their environment. Despite the differences in the mechanism of action of substance use or other addictions, such as gambling or even video games, numerous experimental and clinical data show that the neurochemical mechanisms underlying the formation of various types of addictions are almost the same and primary involving changes in the mesolimbic dopamine system. This review highlights the internal neurochemical mechanisms underlying the formation of various types of addictions and modern approaches to treatment.

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Nemets

St. Petersburg State University

Хат алмасуға жауапты Автор.
Email: v.v.nemets@spbu.ru
Ресей, St. Petersburg

V. Grinevich

Sirius University of Science and Technology, Sirius Federal Territory

Email: v.v.nemets@spbu.ru
Ресей, Krasnodar Region

R. Gainetdinov

Sirius University of Science and Technology, Sirius Federal Territory

Email: v.v.nemets@spbu.ru
Ресей, Krasnodar Region

Әдебиет тізімі

  1. Spencer M., Miniño A., Warner M. // Atlanta, Georgia. 2022.
  2. Weiss R.D., Griffin M.L., Mirin S.M. // Am. J. Drug Alcohol Abuse. 1992. V. 18. P. 121–129.
  3. Sinha R. // Ann. N. Y. Acad. Sci. 2008. V. 1141. P. 105–130.
  4. Cheron J., Kerchove d’Exaerde A. de // Transl. Psychiatry. 2021. V. 11. P. 424.
  5. Гриневич В.П., Немец В.В., Крупицкий E.M., Гайнетдинов Р.Р., Будыгин E.A., Region K. // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2022. Т. 56. № 3. С. 13–29.
  6. Nemets V.V., Deal A.L., Sobolev V.E., Grinevich V.P., Gainetdinov R.R., Budygin E.A. // Biomolecules. 2023. V. 13.
  7. Müller C.P., Homberg J.R. // Behav. Brain Res. 2015. V. 277. P. 146–192.
  8. Жуков Д.А. // Юридический Центр Пресс: Санкт-Петербург. 2004. 457 с.
  9. Mena-Moreno T., Testa G. // J. Clin. Med. 2022. V. 11.
  10. DuPont R.L. // Prev. Med. (Baltim). 2018. V. 113. P. 68–73.
  11. Steinfeld M.R., Torregrossa M.M. // Transl. Psychiatry. 2023. V. 13. P. 313.
  12. Steinberg L. // Dev. Rev. 2008. V. 28. P. 78–106.
  13. Naneix F., Marchand A.R. // J. Neurosci. 2012. V. 32. P. 16223–16232.
  14. Saanijoki T., Tuominen L. // Neuropsychopharmacology. 2018. V. 43. P. 246–254.
  15. Ioannou A. // Encycl. Evol. Psychol. Sci. 2021. V. 2137–2138.
  16. Singer B.F., Bryan M.A. // Behav. Brain Res. 2017. V. 324. P. 66–70.
  17. Bloom F.E., Koob G.F. // Science. 1988. V. 242. P. 715–723.
  18. Wise R.A., Robble M.A. // Annu. Rev. Psychol. 2020. V. 71. P. 79–106.
  19. Yan Y., Kong H., Wu E.J., Newman A.H., Xu M. // Neuroscience. 2013. V. 241. P. 32–40.
  20. Schultz W., Tremblay L., Hollerman J.R. // Neuropharmacology. 1998. V. 37. P. 421–429.
  21. Cohen J.Y., Haesler S., Vong L., Lowell B.B., Uchida N. // Nature. 2012. V. 482. P. 85–88.
  22. Nutt D., King L.A., Saulsbury W., Blakemore C. // Lancet. 2007. V. 369. P. 1047–1053.
  23. Efimova E.V., Gainetdinov R.R., Budygin E.A., Sotnikova T.D. // J. Neurogenet. 2016. V. 30.
  24. Aragona B.J., Cleaveland N.A., Stuber G.D., Day J.J., Carelli R.M., Wightman R.M. // J. Neurosci. 2008. V. 28. P. 8821–8831.
  25. Heien M.L.A.V., Khan A.S., Ariansen J.L., Cheer J.F., Phillips P.E.M., Wassum K.M., Wightman R.M. // Proc. Natl. Acad. Sci. U. S. A. 2005. V. 102. P. 10023–10028.
  26. Williams J.E., Wieczorek W., Willner P., Kruk Z.L. // Brain Res. 1995. V. 678. P. 225–232.
  27. Kalivas P.W. // Dialogues Clin. Neurosci. 2007. V. 9. P. 389–397.
  28. Oleson E.B., Talluri S., Childers S.R., Smith J.E., Roberts D.C.S., Bonin K.D., Budygin E.A. // Neuropsychopharmacol. 2009. V. 34. P. 1174–1184.
  29. Phillips P.E.M., Stuber G.D., Helen M.L.A.V., Wightman R.M., Carelli R.M. // Nature. 2003. V. 422. P. 614–618.
  30. Grinevich V.P., Zakirov A.N., Berseneva U.V., Gerasimova E.V., Gainetdinov R.R., Budygin E.A. // Cells. 2022. V. 11.
  31. Bellone C., Lüscher C. // Nat. Neurosci. 2006. V. 9. P. 636–641.
  32. Edwards N.J., Tejeda H.A. // Nat. Neurosci. 2017. V. 20. P. 438–448.
  33. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. // J. Neurosci. 1998. V. 18.
  34. Budygin E.A., Brodie M.S., Sotnikova T.D., Mateo Y., John C.E., Cyr M., Gainetdinov R.R., Jones S.R. // Proc. Natl. Acad. Sci. U. S. A. 2004. V. 101. P. 7781–7786.
  35. Savchenko A., Targa G., Fesenko Z., Leo D., Gainetdinov R.R., Sukhanov I. // Biomolecules. 2023. V. 13. P. 1–20.
  36. Adinolfi A., Zelli S., Leo D., Carbone C., Mus L., Illiano P., Alleva E., Gainetdinov R.R., Adriani W. // Behav. Brain Res. 2019. V. 359. P. 516–527.
  37. Martin D., Le J.K. // Encycl. Toxicol. Fourth Ed. Vol. 1–9. 2023. V. 1. P. V1–427–V1–433.
  38. Вали Г. // Организация Объединенных Наций. Всемирный Доклад о Наркотиках. 2022.
  39. Dulcan M.K. // J. Child Adolesc. Psychopharmacol. 1990. V. 1. P. 7–20.
  40. Castells X., Blanco-Silvente L., Cunill R. // Cochrane Database Syst. Rev. 2018. V. 8. P. CD007813.
  41. Zhang L., Li L., Andell P. // JAMA Psychiatry. 2024. V. 81. P. 178–187.
  42. Pathan H., Williams J. // Br. J. Pain. 2012. V. 6. P. 11–16.
  43. Krupitsky E., Zvartau E., Woody G. // Curr. Psychiatry Rep. 2010. V. 12. P. 448–453.
  44. Hassanian-Moghaddam H. // Hum. Exp. Toxicol. 2014. V. 33. P. 561–567.
  45. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. // Lancet. 2011. V. 377. P. 1506–1513.
  46. Pauly N.J., Delcher C. // J. Manag. Care Spec. Pharm. 2020. V. 26. P. 246–252.
  47. Tsui J.I., Rossi S.L. // PLoS One. 2024. V. 19. P. 1–20.
  48. Lingford-Hughes A.R., Davies S.J.C. // Br. Med. Bull. 2003. V. 65. P. 209–222.
  49. Grinevich V.P., Krupitsky E.M., Gainetdinov R.R., Budygin E.A. // Front. Behav. Neurosci. 2021. V. 15.
  50. Koob G.F. // Biol. Psychiatry. 2020. V. 87. P. 44–53.
  51. Elvig S.K., McGinn M.A., Smith C., Arends M.A., Koob G.F., Vendruscolo L.F. // Pharmacol. Biochem. Behav. 2021. V. 204. P. 173155.
  52. Bruchas M.R., Land B.B. // PLoS One. 2009. V. 4. P. e8528.
  53. Beck A., Heinz A. // Dtsch. Arztebl. Int. 2013. V. 110. P. 711–715.
  54. Addicott M.A., Marsh‐Richard D.M., Mathias C.W., Dougherty D.M. // Alcohol. Clin. Exp. Res. 2007. V. 31. P. 1883–1890.
  55. Budygin E.A., Phillips P.E.M., Robinson D.L., Kennedy A.P., Gainetdinov R.R., Wightman R.M. // J. Pharmacol. Exp. Ther. 2001. V. 297.
  56. Quertemont E., Didone V. // Alcohol Res. Heal. 2006. V. 29. P. 258–265.
  57. Budygin E.A., Bass C.E., Grinevich V.P., Deal A.L., Bonin K.D., Weiner J.L. // iScience. 2020. V. 23.
  58. Krupitsky E., Woody G.E., Zvartau E., O’Brien C.P. // Lancet. 2010. V. 376. P. 1145.
  59. Krupitsky E.M., Masalov D.V., Didenko T.Y., Burakov A.M., Romanova T.N., Zvartau E.E., Woody G. // Eur. Addict. Res. 2001. V. 7. P. 87–88.
  60. Wu R., Liu J., Wang K. // Behav. Brain Res. 2020. V. 390. P. 112641.
  61. Frycz B.A., Nowicka K. // Addict. Biol. 2023. V. 28.
  62. Bradaia A., Trube G. // Proc. Natl. Acad. Sci. U. S. A. 2009. V. 106. P. 20081–20086.
  63. Berry M.D., Gainetdinov R.R., Hoener M.C., Shahid M. // Pharmacol. Ther. 2017. V. 180. P. 161–180.
  64. Belgers M., Van Eijndhoven P. // J. Clin. Med. 2022. V. 11.
  65. Kearney-Ramos T.E. // Biol. Psychiatry. Cogn. Neurosci. Neuroimaging. 2018. V. 3. P. 599–609.
  66. Jha P. // Nat. Rev. Cancer. 2009. V. 9. P. 655–664.
  67. Rigotti N.A., Kruse G.R. // JAMA. 2022. V. 327.
  68. Begh R., Lindson-Hawley N., Aveyard P. // BMC Med. 2015. V. 13. P. 257.
  69. Le Foll B., Piper M.E. // Nat. Rev. Dis. Prim. 2022. V. 8. P. 19.
  70. Carcoba L.M., Orfila J.E. // Dev. Neurosci. 2014. V. 36. P. 347–355.
  71. Salas R., Sturm R. // J. Neurosci. 2009. V. 29. P. 3014–3018.
  72. Belluzzi J.D., Wang R., Leslie F.M. // Neuropsychopharmacology. 2005. V. 30. P. 705–712.
  73. Heatherton T.F., Kozlowski L.T. // Br. J. Addict. 1989. V. 84. P. 791–799.
  74. Takahashi T., Lapham G. // Addict. Sci. Clin. Pract. 2017. V. 12. P. 17.
  75. Heikkinen H., Jallinoja P. // Nicotine Tob. Res. 2008. V. 10. P. 1199–1207.
  76. Karila L., Roux P. // Curr. Pharm. Des. 2014. V. 20. P. 4112–4118.
  77. Sharma P., Murthy P., Bharath M.M.S. // Iran. J. Psychiatry. 2012. V. 7. P. 149–156.
  78. Martin-Santos R., Crippa J.A. // Curr. Pharm. Des. 2012. V. 18. P. 4966–4979.
  79. Sierra S., Luquin N. // Brain Struct. Funct. 2015. V. 220. P. 2721–2738.
  80. Davis M.I., Crittenden J.R. // PLoS One. 2018. V. 13. P. e0191436.
  81. Glass M., Dragunow M., Faull R.L. // Neuroscience. 1997. V. 77. P. 299–318.
  82. Oleson E.B., Cheer J.F. // Cold Spring Harb. Perspect. Med. 2012. V. 2.
  83. Justinova Z., Solinas M. // J. Neurosci. 2005. V. 25. P. 5645–5650.
  84. Castañeda E., Moss D.E. // Pharmacol. Biochem. Behav. 1991. V. 40. P. 587–591.
  85. Shrivastava A., Johnston M. // Indian J. Psychiatry. 2014. V. 56. P. 8–16.
  86. Ream G.L., Benoit E. // Drug Alcohol Depend. 2008. V. 95. P. 199–208.
  87. Stein D.J., Hollander E., Liebowitz M.R. // J. Neuropsychiatry Clin. Neurosci. 1993. V. 5. P. 9–17.
  88. Petry N.M., Blanco C. // J. Gambl. Stud. 2014. V. 30. P. 493–502.
  89. Clark L., Averbeck B. // J. Neurosci. 2013. V. 33. P. 17617–17623.
  90. Bechara A., Damasio A.R., Damasio H., Anderson S.W. // Cognition. 1994. V. 50. P. 7–15.
  91. Must A., Horvath S., Nemeth V.L., Janka Z. // Front. Psychol. 2013. V. 4. P. 61017.
  92. Zeeb F.D., Robbins T.W., Winstanley C.A. // Neuropsychopharmacology. 2009. V. 34. P. 2329–2343.
  93. Seo M., Lee E., Averbeck B.B. // Neuron. 2012. V. 74. P. 947–960.
  94. Shiv, Loewenstein, Bechara, Damasio H., Damasio A.R. // Psychol. Sci. 2005. V. 16.
  95. Xue G., Lu Z., Levin I.P., Bechara A. // Hum. Brain Mapp. 2011. V. 32.
  96. Ambermoon P., Carter A., Hall W.D. // Addiction. 2011. V. 106. P. 283–293.
  97. Linnet J., Møller A., Peterson E., Gjedde A., Doudet D.J. // Addiction. 2011. V. 106.
  98. Nemets V.V., Vinogradova E.P., Zavialov V., Grinevich V.P., Budygin E.A., Gainetdinov R.R. // Biomolecules. 2024. V. 14. P. 14.
  99. Nemets V.V., Vinogradova E.P. // Natl. Psychol. J. 2017. V. 2. P. 59–72.
  100. Cabib S., Puglisi-Allegra S. // Neurosci. Biobehav. Rev. 2012.
  101. Nemets V.V., Vinogradova E.P. // Natl. Psychol. J. 2017. V. 2. P. 59–72.
  102. Rogers R.D. // Neuropsychopharmacology. 2011. V. 36. P. 114–132.
  103. Kelsoe J.R. // Nature. 2010. V. 468. P. 1049–1050.
  104. Dalley J.W., Roiser J.P. // Neuroscience. 2012. V. 215. P. 42–58.
  105. Lage G.M. // PLoS One. 2011. V. 6. P. 1–5.
  106. Oades R.D., Lasky-Su J. // Behav. Brain Funct. 2008. V. 4. P. 48.
  107. Popova N.K. // Bioessays. 2006. V. 28. P. 495–503.
  108. Naumenko V.S., Ponimaskin E.G., Popova N.K. // Vavilov J. Genet. Breed. 2016. V. 20. P. 180–190.
  109. Murphy S.E., Longhitano C. // J. Cogn. Neurosci. 2009. V. 21. P. 1709–1719.
  110. Crockett M.J., Clark L. // Emotion. 2010. V. 10. P. 855–862.
  111. Schweighofer N., Bertin M. // J. Neurosci. 2008. V. 28. P. 4528.
  112. Bekir S., Çelik E. // An. Psicol. 2019. V. 35. P. 444–452.
  113. Mohammad S., Jan R.A., Alsaedi S.L. // Cureus. 2023. V. 15.
  114. Young K. // Am. J. Fam. Ther. 2009. V. 37. P. 355–372.
  115. Gentile D.A., Choo H. // Pediatrics. 2011. V. 127. P. e319-29.
  116. Carpita B., Muti D. // Life. 2010. V. 11. P. 268–276.
  117. Weinstein A.M. // Am. J. Drug Alcohol Abuse. 2010. V. 36. P. 268–276.
  118. Nutt D.J., Lingford-Hughes A. // Nat. Rev. Neurosci. 2015. V. 16. P. 305–312.
  119. Volkow N.D., Fowler J.S., Wang G.-J., Swanson J.M. // Mol. Psychiatry. 2004. V. 9. P. 557–569.
  120. Pelletti G., Garagnani M., Rossi F., Roffi R., Banchini A., Pelotti S. // Forensic Sci. Med. Pathol. 2018. V. 14. P. 442–449.
  121. Pierce M., Hayhurst K., Bird S.M. // Drug Alcohol Depend. 2017. V. 179. P. 309.
  122. Craig A. Anderson, Karen E. Dill // J. Pers. Soc. Psychol. 2000. V. 78. P. 772–790.
  123. Ferguson C.J., Dyck D. // Aggress. Violent Behav. 2012. V. 17. P. 220–228.
  124. Froböse M.I., Cools R. // Curr. Opin. Behav. Sci. 2018. V. 22. P. 121–127.
  125. Winstanley C.A., Theobald D.E.H., Dalley J.W., Robbins T.W. // Neuropsychopharmacology. 2005. V. 30. P. 669–682.
  126. Tsybko A., Ilchibaeva T., Kozhemyakina R., Eremin D., Naumenko V. // IBRO Reports. 2019. V. 6. P. S57.
  127. Dongju Seo, Christopher J. Patrick, Patrick J. Kennealy // Curr. Opin. Psychiatry. 2008. V. 13. P. 585–588.
  128. Ramey T., Regier P.S. // CNS Spectr. 2019. V. 24. P. 102–113.
  129. Gacek P., Conner T.S. // Addict. Biol. 2008. V. 13. P. 440–448.
  130. Zupanc T., Pregelj P. // Neurosci. Lett. 2011. V. 490. P. 78–81.
  131. Hatoum A.S., Colbert S.M.C. // Nat. Ment. Heal. 2023. V. 1. P. 210–223.
  132. Enoch M.-A. // Curr. Psychiatry Rep. 2012. V. 14. P. 150–158.
  133. Kibitov A.O., Chuprova N.A. 2015. V. 115. P. 51–58.
  134. Sinha R. // Alcohol Res. 2012. V. 34. P. 432–440.
  135. Wang W., Zeng F. // Trends Cogn. Sci. 2015. V. 22. P. 439–444.
  136. Sora I., Hall F.S., Andrews A., Itokawa M., Li X., Uhl G.R. // Proc. Natl. Acad. Sci. U. S. A. 2001. V. 98.
  137. Cox S.M.L., Benkelfat C., Dagher A., Delaney J.S., Durand F., Kolivakis T., Casey K.F., Leyton M. // Br. J. Psychiatry. 2011. V. 199. P. 391–397.
  138. Wu P., Hoven C.W., Liu X., Cohen P., Fuller C.J., Shaffer D. // Suicide Life. Threat. Behav. 2004. V. 34. P. 408–420.
  139. Hooper C.J., Luciana M., Conklin H.M., Yarger R.S. // Dev. Psychol. 2004. V. 40.
  140. Volkow N.D., Michaelides M., Baler R. // Physiol. Rev. 2019. V. 99. P. 2115–2140.
  141. Gould T.J. // Addict. Sci. Clin. Pract. 2010. V. 5. P. 4–14.
  142. Substance Abuse and Mental Health Services Administration (US); 1997. TIP. No. 24. A Guide to Substance Abuse Services for Primary Care Clinicians – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64830/
  143. Востриков В.В., Зеленцов К.Е., Майорова О.В., Востриков М.В., Павленко В.П., Шабанов П.Д. // Обзоры по клинической фармакологии и лекарственной терапии. 2008. Т. 6, № 4, С. 26–52.
  144. Linke S.E., Ussher M. // Am. J. Drug Alcohol Abuse. 2014. V. 41. P. 7.
  145. Sukhanov I., Dorofeikova M., Dolgorukova A., Dorotenko A., Gainetdinov R.R. // Front. Pharmacol. 2018. V. 9. P. 1–10.
  146. Achat-Mendes C., Lynch L.J., Sullivan K.A., Vallender E.J., Miller G.M. // Pharmacol. Biochem. Behav. 2012. V. 101. P. 201–207.
  147. Бортников Н.С., Драволина О.А., Суханов И.М., Куварзин С.Р., Гайнетдинов Р.Р., Звартау Э.Э. // Вопросы Наркологии. 2021. Т 82. № 5. С. 52–72.
  148. Leo D., Sukhanov I., Zoratto F., Illiano P., Caffino L., Sanna F., Messa G., Emanuele M., Esposito A., Dorofeikova M. // J. Neurosci. 2018. V. 38. P. 1959–1972.
  149. Pei Y., Asif-Malik A., Canales J.J. // Front. Neurosci. 2016. V. 10. P. 148.
  150. Espinoza S., Lignani G., Caffino L., Maggi S., Sukhanov I. // Neuropsychopharmacology. 2015. V. 40. P. 2217–2227.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Schematic representation of the effect of narcotic substances (NS) on the functioning of various parts of the human brain. The figure shows a diagram of the interaction of various parts of the human brain under normal conditions, with short-term use of NS and during long-term use, as well as the main behavioral manifestations and possible consequences of NS use. The interaction of various parts of the brain is based on neurotransmitter neurotransmission, which has an activating (DA, GLU, NA) and inhibitory (GABA, SER) effect on various parts of the brain. The figure shows the limbic parts of the brain (Pfc - prefrontal cortex, NAc - nucleus accumbens, Am - amygdala, VTA - ventral tegmental area), as well as Rn - raphe nuclei (source of SER neurotransmission), LC - locus coeruleus (source of NA neurotransmission).

Жүктеу (517KB)
Метадеректер

© Russian Academy of Sciences, 2025